Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors. Its primary program, ficerafusp alfa, is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a transforming growth factor beta (TGF-β) binding domain. This design targets EGFR-expressing tumor cells while modulating TGF-β signaling in the tumor microenvironment to overcome fibrotic barriers, enhance immune cell penetration, and promote deeper anti-tumor responses. The therapy is being advanced in clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative cases with high unmet need, in combination with pembrolizumab. Evaluation is also underway in metastatic colorectal cancer, both as monotherapy and in combinations, highlighting its potential across multiple EGFR- and TGF-β-driven solid tumor indications. Incorporated in 2018 and headquartered in Boston, Massachusetts, Bicara Therapeutics Inc. operates within the biotechnology sector, emphasizing oncology innovation through targeted tumor microenvironment modulation.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Claire Mazumdar Clemon M.B.A., Ph.D.

Employees

103

Headquarters

Boston, MA, United States

Website

www.bicara.com